Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
6
×
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
crispr
crispr therapeutics
crispr-cas9
deals
fda
gene editing
indiana blog main
indiana top stories
messenger rna
roche
startups
alzheimer's disease
amgen
What
crispr
6
×
bio
roundup
cas
big
ceo
editas
medicine
scientists
therapeutics
today
acquisitions
albert
alliance
allogene
available
based
beam
biggest
biosciences
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
calls
cancer
changing
cheaper
color
company
crime
days
departure
develop
diagnostics
diversity
drug
Language
unset
unknown
Current search:
crispr
×
biotech
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M